-
Mashup Score: 9BCL2 inhibition: back to the future! - 6 day(s) ago
In this issue of Blood, Liu and colleagues report the preliminary characterization of a new BCL2-specific inhibitor (BCL2i), sonrotoclax, which not only bi
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5The paradox of platypnoea–orthodeoxia syndrome - 9 day(s) ago
The Internal Medicine Journal (IMJ) is a leading internal medicine publication from the Royal Australasian College of Physicians publishing original medical research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis - 12 day(s) ago
Abstract. Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 29
PURPOSE A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS Patients with either MRD (≥1 log10 rise) or oligoblastic relapse (blasts 5%-15%) received venetoclax 600 mg once daily D1-28 plus LDAC once daily D1-10 in 28-day cycles. The primary objective was MRD response in the MRD relapse cohort or complete remission (CR/CRh/CRi) in the oligoblastic relapse cohort. RESULTS Forty-eight adults with either MRD (n = 26) or oligoblastic (n = 22) relapse were enrolled. Median age was 67 years (range, 18-80) and 94% had received previous intensive chemotherapy. Patients received a median of four cycles of therapy; 17% completed ≥12 cycles. Patients with oligoblastic relapse had more grade ≥3 anemia (32% v 4%; P = .02) and infections (36% v 8%; P = .03), whereas grade 4 neutropenia (32 v 23%) or thrombocytopenia (27 v 15%) were comparable with the MR
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 19ASH | FDA Collaboration: A Workshop on Regulatory Science in Hematology - Hematology.org - 15 day(s) ago
ASH | FDA Collaboration: A Workshop on Regulatory Science in Hematology
Source: www.hematology.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 69
Use of surrogates as primary endpoints is commonplace in hematology/oncology clinical trials. As opposed to prognostic markers, surrogates are endpoints th
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 65
Use of surrogates as primary endpoints is commonplace in hematology/oncology clinical trials. As opposed to prognostic markers, surrogates are endpoints th
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 65
Use of surrogates as primary endpoints is commonplace in hematology/oncology clinical trials. As opposed to prognostic markers, surrogates are endpoints th
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 158
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5More Robust Data Should Be Required Before Drugs Fully Approved - 1 month(s) ago
Abstract: Many cancer drugs are converted from accelerated to regular approval by the FDA despite a lack of proof that patients will reap clinically meaningful benefits from their use. Researchers suggest the FDA withhold regular approval of a drug until its manufacturer implements a trial design that can robustly demonstrate its benefit to patients.
Source: aacrjournals.orgCategories: General Medicine News, Partners & KOLsTweet
RT @MJAhearne: BCL2 inhibition: back to the future! https://t.co/y9FDRGC9GI "God is in the detail". Fantastic commentary, penned by two es…